Preview

Пульмонология

Расширенный поиск

Спирива - эффективный препарат, уменьшающий одышку и частоту обострений при хронической обструктивной болезни легких (данные клинических испытаний)

Полный текст:

Об авторах

C. И. Овчаренко
Московская медицинская академия им. И.М.Сеченова
Россия


Е. П. Голикова
Московская медицинская академия им. И.М.Сеченова
Россия


Список литературы

1. Синопальников А .И ., Клячкина И.Л. Тиотропиум бромид: новые возможности в лечении хронической обструктивной болезни легких. Рос. мед. журн. 2001; 9 (15): 658.

2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. CareMed. 1995; 152: S77-S121; 2001; 163: 1256-1276.

3. Barnes P. Tiotropium bromide: a new long-acting anticholinergic bronchodilator. In: Barnes P., Buist A.S., eds. The rôle of anticholinergics in chronic obstructive pulmonary disease and chronic asthma. Macclesfied Cheshire, UK: Gardiner-Caldwell Communications Limited; 1997. 126-136.

4. Briggs D.D., Kuritzky L., Boland C. et al. Early détection and management of COPD: Guidelines from the National COPD Awareness Panel (NCAP). J Respir Dis. 2000; 21: S1-S21.

5. Casabury R., Mahler D.A., Jones P.W. et al. A long-term élé­vation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.

6. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agent alone. A 65-day multicenter trial. Chest 1994; 105: 1411-1419.

7. The COPD guidelines group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl.5): S1-S28.

8. Doherty D.E. Management of the Symptomatic Patient. Clin. Cornerstone 2003; 5(1): 17-27.

9. Donohue J.F., van Noorcl J.A., Bateman E. et at. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.

10. Friedman M ., Auerbach D., Campbell S. et al. Tiotropium in patients with COPD. Am. J. Respir. Crit. Care Med. 1998; 157: A804.

11. Friedman M ., Serby C.W., Shailendra S.M. et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone. Chest 1999; 115: 635-641.

12. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Updated 2003). National Institutes of Health; National Heart, Lung and Blood Institute; 2003.

13. Greefhorst A.P.M ., Vincken W., van Noord J.A. et al. Improvement in perceived dyspnea in COPD patients receiving tiotropium vs ipratropium bromide (atroventT). Eur. Respir. J. 2000; 16 (suppl.31): 54s.

14. Gross N.J., Skorodin M.S. Anticholinergic antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 1984; 129: 856-870.

15. Guyatt G.H., Townsend M ., Pugsley S.O. et al. Bronchodilators in chronic airflow limitation. Effects on airway function, exercise capacity, and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.

16. Ikeda A., Nishimura K., Koyama H. et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107: 401-405.

17. Jones P. W., Koch P., Menjoge S.S et al. The Impact of COPD exacerbations on health-related quality of life (health status) is attenuated by tiotripium. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A771.

18. Kotch A., Mejoge S.S., Serby C.W. et al. Nocturnal symptoms and severity of disease in COPD. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A906.

19. Littner M ., Auerbach D., Campbell S. et al. The Bronchodilator effects of tiotropium in stable COPD. Am. J. Respir. Crit. Care Med. 1997; 155: A282.

20. Mahler D.A., Weinberg D.H., Wells C.K. et al. Baseline dyspnea index and transitional dyspnea index: the measurement of dyspnea. Chest 1984; 85: 751-758.

21. Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.

22. Mahler D.A., Montner P., Brazinsky S.A. et al. Tiotropium (SpirivaT): A new, long-acting anticholinergic bronchodilator improves dyspnea in patients with COPD. Am. J. Respir. Crit. Care Med. 2000; 161: A892.

23. McNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S-317S.

24. Murray D., Altose M .D. Approaches to slowing the progression of COPD. Curr. Opin. Pulm. Med. 2003; 9 (2): 125-130.

25. National COPD Awareness Panel (NCAP). COPD: Achieving best management at the front line of care. J. Respir. Dis. 2002; 23: S1-S52.

26. Pauwels R., Anthonisen N., B ailey W.C. et al. Executive summary of global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute-World Health Organization (NHLBI-WHO) workshop report; 2001.

27. Pauwels R.A., Menjoge S.S., Kesten S. COPD Exacerbations and decline in FEVi: the role of tiotropium. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A280.

28. Rennard S.I., Serby C.W., Ghafouri M ., et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996; 110: 62-70.

29. Rennard S.I., Anderson W., ZuWallack R. et al. Use of a longacting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.

30. Rennard S.I., Farmer S.G. COPD in 2001: a major challenge for medicine, the pharmaceutical industry, and society. Chest 2002, 121: 113S-115S.

31. Snow V., Lascher S., Mottur-P ilson C., for the Joint Expert Panel on COPD. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 2001; 134: 595-599.

32. Tashkin D., Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123 (5): 144-1449.

33. Van Noord J., Bantje Th., Eland M . et al. Superior efficacy of tiotropium compared to ipratropium as a maintenance bronchodilator in COPD. Am. J. Respir. Crit. Care Med. 1999; 159 (3): A525.

34. Vincken W., van Noord J.A., Greefhorst A.P.M . et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.


Для цитирования:


Овчаренко C.И., Голикова Е.П. Спирива - эффективный препарат, уменьшающий одышку и частоту обострений при хронической обструктивной болезни легких (данные клинических испытаний). Пульмонология. 2003;(6):103-107.

For citation:


Ovcharenko S.I., Golikova E.P. Spiriva is an effective drug reducing dyspnoe and exacerbation rate in COPD (clinical search findings). PULMONOLOGIYA. 2003;(6):103-107. (In Russ.)

Просмотров: 11


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)